HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hypoxia-reoxygenation-induced endothelial barrier failure: role of RhoA, Rac1 and myosin light chain kinase.

Abstract
Hypoxia-reoxygenation induces loss of endothelial barrier function and oedema formation, which presents a major impediment for recovery of the organ. The integrity of the endothelial barrier is highly dependent on its contractile machinery and actin dynamics, which are precisely regulated by Rho GTPases. Perturbed activities of these Rho-GTPases under hypoxia-reoxygenation lead to derangement of the actin cytoskeleton and therefore may affect the integrity of the endothelial barrier. The aim of the present study was to analyse the role of these GTPases in regulating endothelial barrier function during hypoxia-reoxygenation in cultured porcine aortic endothelial cells and isolated perfused rat hearts. Hypoxia-reoxygenation induced an increase in albumin permeability of endothelial monolayers accompanied by an activation of the endothelial contractile machinery, derangement of the actin cytoskeleton and loss of VE-cadherin from cellular junctions. Inhibition of contractile activation with ML-7 partially protected against hypoxia-reoxygenation-induced hyperpermeability. Likewise, reoxygenation caused an increase in RhoA and a reduction in Rac1 activity accompanied by enhanced stress fibre formation and loss of peripheral actin. Inhibition of RhoA/rho kinase (Rock) signalling with RhoA or Rock inhibitors led to a complete depolymerisation and derangement of the actin cytoskeleton and worsened hypoxia-reoxygenation-induced hyperpermeability. Activation of Rac1 using a cAMP analogue, 8-CPT-O-Me-cAMP, which specifically activates Epac/Rap1 signalling, restored peripheral localisation of actin and VE-cadherin at cellular junctions and abrogated reoxygenation-induced hyperpermeability. Similar results were reproduced in isolated saline-perfused rat hearts. These data show that activation of Rac1 but not the inhibition of RhoA preserves endothelial integrity against reoxygenation-induced loss of barrier function.
AuthorsMuhammad Aslam, Klaus-Dieter Schluter, Susanne Rohrbach, Amir Rafiq, Sabiha Nazli, Hans Michael Piper, Thomas Noll, Rainer Schulz, Dursun Gündüz
JournalThe Journal of physiology (J Physiol) Vol. 591 Issue 2 Pg. 461-73 (Jan 15 2013) ISSN: 1469-7793 [Electronic] England
PMID23090948 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 8-(4-chloro-phenylthio)-2'-O-methyladenosine-3'-5'-cyclic monophosphate
  • Actins
  • Antigens, CD
  • Cadherins
  • Guanine Nucleotide Exchange Factors
  • cadherin 5
  • Cyclic AMP
  • rho-Associated Kinases
  • Myosin-Light-Chain Kinase
  • rac1 GTP-Binding Protein
  • rhoA GTP-Binding Protein
  • Calcium
Topics
  • Actins (metabolism)
  • Adherens Junctions (metabolism)
  • Animals
  • Antigens, CD (metabolism)
  • Aorta (cytology, physiology)
  • Cadherins (metabolism)
  • Calcium (metabolism)
  • Cell Hypoxia
  • Cyclic AMP (analogs & derivatives, pharmacology)
  • Endothelial Cells (metabolism)
  • Guanine Nucleotide Exchange Factors (antagonists & inhibitors, metabolism)
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • In Vitro Techniques
  • Muscle, Smooth, Vascular (physiology)
  • Myosin-Light-Chain Kinase (metabolism)
  • Permeability
  • Rats
  • Signal Transduction
  • Stress Fibers (metabolism)
  • Swine
  • Vasoconstriction
  • rac1 GTP-Binding Protein (metabolism)
  • rho-Associated Kinases (metabolism)
  • rhoA GTP-Binding Protein (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: